Stage IV HR-Positive Invasive Lobular Carcinoma: Leanne's Patient Story

Patient Info: Leanne, Female, 50s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Brain

Leanne was first diagnosed in 2015 with Stage III triple-positive ILC and then diagnosed with metastatic lobular breast cancer with brain metastasis on April 4, 2018, causing major neurologic and work limitations.

Lobular Breast Cancer AllianceRead more →

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient StoryRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Shari's Patient Story

Patient Info: Shari S., Female | Stage IV

Biomarkers: ER-positive, PR-positive and HER2-positive; no inherited cancer mutation was identified

Metastatic Site: Brain; other initial metastatic sites were not named

Systemic imaging after chemotherapy showed no active disease, but brain metastases later required stereotactic radiation. Shari remained stage 4, continued Herceptin every 3 weeks and underwent brain MRI every 3–4 months.

The Patient StoryRead more →

Stage IV Triple-Negative Breast Cancer: Janice's Patient Story

Patient Info: Janice, Female, Under 40 | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: Other sites not specified

Living with incurable Stage IV triple-negative breast cancer while advocating for dose adjustments, symptom management, and balancing quality of life with survival.

The Patient StoryRead more →

Stage IV Triple-Negative Breast Cancer: Erin's Patient Story

Patient Info: Erin, Female | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative; later tumor responded to androgen signaling

Metastatic Site: Lung; brain

As of June 2026, Erin was living with metastatic triple-negative breast cancer involving lung and brain, with tumors shrinking on ongoing Gemzar plus carboplatin chemotherapy every 2 weeks.

The Patient StoryRead more →

Metastatic triple-negative breast cancer with orbital and bone metastases responding to nab-paclitaxel plus everolimus

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary breast cancer was ER-low, PR/HER2 negative. Orbital metastasis was triple-negative with AKT1 exon 4 mutation.

Metastatic Site: right orbit/orbital mass; bone

At 6-month follow-up, systemic disease was stable, ocular symptoms had significantly improved, orbital metastases were stable on MRI, and the response was described as RECIST partial response/progression-free interval while treatment continued.

PubMed CentralRead more →

Stage IIB triple-negative metaplastic breast cancer with early metastatic recurrence: durable response to pembrolizumab-based therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Triple-negative metaplastic breast cancer with PD-L1 CPS 83.2, BRCA1/2 negative

Metastatic Site: lung, sternum

As of May 2026, she had more than 30 months of disease control after pembrolizumab-based therapy for early recurrent metastatic metaplastic breast cancer, with only mild residual sternal uptake and no disease progression.

PubMed CentralRead more →

Stage 4 breast cancer: 4 years and counting

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor: hormone receptor-positive; HER2 1+. Metastatic recurrence: triple-negative breast cancer.

Metastatic Site: liver, bone, lung, supraclavicular lymph nodes,…

After response of choroidal metastases to eye radiation plus sacituzumab govitecan, disease progressed in February 2023 with cerebellar and pituitary brain lesions; she developed obstructive hydrocephalus, entered hospice in May 2023, and died in June 2023.

PubMed CentralRead more →

Metastatic triple-negative breast cancer with sacituzumab-govitecan pneumonitis and progression

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: lung

Sacituzumab-govitecan pneumonitis improved with corticosteroids and half-dose rechallenge did not reproduce pneumonitis, but follow-up CT showed one new pulmonary metastasis and enlargement of previous lung metastases; PFS on sacituzumab govitecan was 5.37 months.

PubMed CentralRead more →

Stage IV triple-negative invasive lobular breast cancer with HER2 mutations: complete metabolic response to trastuzumab deruxtecan

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Triple-negative invasive lobular breast cancer with HER2-low/dubious staining and HER2 FISH-negative; somatic ERBB2/HER2 and mutations.

Metastatic Site: iliac bone lesions / bone metastases

As of January 2026, metastatic triple-negative invasive lobular breast cancer with HER2 mutations had a sustained complete metabolic response to trastuzumab deruxtecan for 20 months, with dose reduction for neutropenia and no pulmonary toxicity.

PubMed CentralRead more →

Stage IV Triple-Negative Breast Cancer: Chelsey's Patient Story

Patient Info: Chelsey Pickthorn, Female | Stage IV

Biomarkers: Triple-negative breast cancer

As of December 2025, Chelsey was described as a patient advocate living with Stage IV triple-negative breast cancer, with the conversation focused on LGBTQ+ sexuality, relationships, disclosure, caregiving, body image, and inclusive cancer care.

Triple-negative breast cancer with occult metastasis in parathyroid and ectopic thyroid adenomas: complete remission after chemotherapy

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Triple-negative breast cancer. Metastatic deposits were CK7 positive and negative for ER, HER2

Metastatic Site: parathyroid adenoma; ectopic thyroid adenoma /…

As of December 2025, she remained in complete remission 1 year after systemic chemotherapy for triple-negative breast cancer with occult metastatic deposits in parathyroid and ectopic thyroid adenomas.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Paul's Patient Story

Patient Info: Paul Forgette, Male, 60s | Stage IV

Biomarkers: HER2-positive; triple-positive breast cancer; CHEK2 mutation

Metastatic Site: Bones; lymph nodes

By October 2025, 9 months after starting Enhertu, Paul’s Stage IV HER2-positive male breast cancer was described as dormant, not cured, with continued City of Hope care and integrative support.

City of HopeRead more →

Stage IV Triple-Negative Breast Cancer: Nicole's Patient Story

Patient Info: Nicole, Female, 40s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: liver

Nicole remained in active treatment for liver-metastatic triple-negative breast cancer, with meaningful response after switching to an antibody-drug conjugate and then undergoing mastectomy.

The Patient StoryRead more →

Deltra: Stage IV triple-negative breast cancer and sexual health advocacy story

Patient Info: Deltra, Female | Stage IV

Biomarkers: Triple-negative breast cancer

As of October 2025, Deltra was described as a mother of 5 living with triple-negative metastatic breast cancer and advocating for better sexual-health conversations in oncology care.

Triple-negative metastatic breast cancer with pituitary metastasis: symptom relief after debulking

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Pituitary metastasis was triple-negative breast cancer with no HER2 amplification.

Metastatic Site: liver; bone/skull; right breast; left orbit/optic…

Transsphenoidal debulking relieved visual symptoms and 6-month MRI showed no pituitary recurrence, while known metastatic breast cancer at other sites remained part of her ongoing cancer course.

PubMed CentralRead more →

Stage IV Triple-Negative Breast Cancer: Melissa's Patient Story

Patient Info: Melissa Fouts, Female | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: Outside the lungs / pleural area

As of September 2025, Melissa had been on low-dose eribulin for almost 7 years; 6 metastatic nodules outside the lungs had shrunk and stabilized, with 3 nearly undetectable on scans.

MD AndersonRead more →

Stage 4 triple-negative breast cancer: NED after adrenalectomy

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative; CA 15-3 elevated at recurrence; normalized post-surgery

Metastatic Site: adrenal gland

After adrenalectomy, serum CA15-3 and metanephrine/normetanephrine levels normalized, and the preoperative workup had found no other metastatic disease.

PubMed CentralRead more →

Stage IV Triple-Negative Breast Cancer: Maggie's Survivor Story

Patient Info: Maggie, Female | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: lungs, lymph nodes; possible liver

Diagnosed in 2022 with de novo Stage IV triple-negative breast cancer involving the lungs and lymph nodes, with possible liver involvement. After entering a chemotherapy/immunotherapy clinical trial, she reported being cancer-free / no evidence of disease for well over 1 year as of February 2025.

The Patient StoryRead more →

Metastatic breast cancer with receptor evolution: sequential endocrine, immunotherapy, CDK4/6, and antibody-drug conjugate treatment

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Markers changed over time: initial tumor ER-positive/HER2-negative; local recurrence triple-negative/HER2-low; pleural fluid ER-negative.

Metastatic Site: mediastinal lymph nodes, pleura; pulmonary nodules…

More than 7 years after diagnosis, she remained on sequential systemic therapy for metastatic breast cancer, with at least a partial response 3 months after starting sacituzumab govitecan for presumed triple-negative pleural disease.

PubMed CentralRead more →

Deltra: Stage IV Breast Cancer

Patient Info: Deltra James, Female, Under 40 | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

As of December 2024, Deltra James was living with de novo Stage IV triple-negative metastatic breast cancer and advocating for sexual-health and intimacy conversations in metastatic care.

Breast Cancer Recurrence in the Small Intestine and Bone More Than 5 Years After Diagnosis

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial ER-positive, PR-positive, HER2-negative; metastatic lesion ER-negative, PR-negative, triple negative

Metastatic Site: small intestine, bone, right fallopian tube

More than 5 years after her December 2018 diagnosis, she was alive at 1-year follow-up after metastatic recurrence, with multiple bone metastases still present.

PubMed CentralRead more →

Stage IV Triple-Negative Breast Cancer: Deltra's Patient Story

Patient Info: Deltra James, Female, Under 40 | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

As of November 2024, Deltra James was living with de novo Stage IV triple-negative metastatic breast cancer and discussing dating, confidence, and emotional safety after diagnosis.

Melissa Berry Deltra: Stage IV Breast Cancer

Patient Info: Deltra James, Female, Under 40 | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

As of September 2024, Deltra James was living with de novo Stage IV triple-negative metastatic breast cancer and advocating for confidence and intimacy while living with advanced disease.